Parents of boy with rare eye condition hail ‘amazing' results of gene therapy
Jace, from Connecticut, USA, was diagnosed with leber congenital amaurosis type 4 (LCA4) – a rare inherited eye disease that causes blindness – when he was just a baby.
He was selected for the pioneering gene therapy after his parents had a 'chance encounter' with the UK specialist involved in the trial.
His parents Brendan and DJ, who did not wish to share their surname, said the results have been 'pretty amazing'.
Jace, now six, was one of four children selected to have the treatment by specialists from Moorfields Eye Hospital and UCL Institute of Ophthalmology.
Doctors performed keyhole surgery and injected healthy copies of the affected gene into the retina, the light-sensitive layer of tissue at the back of the eye.
Three to four years on, vision in the treated eyes has 'improved substantially', according to findings now published in The Lancet.
Jace's mum DJ, 35, told the PA news agency: 'Pre-surgery, at around two years old, you could have held up any object, even a couple of inches away from Jace's face, and he would not be able to track it.
'It didn't matter how bright it was, what colour it was, what shape it was.
'And now we get calls and notes home from school that he's stealing phones out of teachers' back pockets, which is hysterical to us.
'Probably not the best thing to be happening in school, but it just goes to show how much growth he's had in his visual abilities over the past four years.
'And that's unheard of with LCA4 – you don't progress to having more vision naturally.
'It's a progression of losing it before the age of four years old. So it's amazing to watch him.'
Dad Brendan, 36, added: 'He's picking up small things off the floor. He's calling out toys.
'He's doing things that are really driven by his sight, that never would have, in our opinion, had been done before or would have been done.
'We can hold up our phone, for example, and he'll tell us, this is our phone from a good distance away. Or hold up a toy, and he can tell us what toy it is.
'If he drops something when he's eating, even if it's the smallest thing, like a Cheerio, or a gummy bear, or whatever it may be, he's able to find it on the tile or on the carpet and pick it up.
'We try to get him to not eat it, but he picks it up, I guess that's a treat for him if he can find it. It's fine with us. It's pretty amazing.'
DJ added that the family feels 'lucky' to have been given the opportunity for treatment.
'There's such a need to amplify how this treatment has been working because we think about all the other parents that are sitting there with their five-month-old scared out of their mind about what their future is going to look like,' she said.
'We were so lucky to have been able to have this option available to us and to Jace.
'No parent wants to not do as much as humanly possible for their child.
'So yes, it's giving the gift of sight to these children, but it's also giving the ability for other parents to be able to make this decision for their child by making the treatment more mainstreamed and available to the masses.'
DJ suspected something was not right with her son when he was eight weeks old and he was not looking at her and smiling.
His eyes would dart around and roll, which the couple later found out was nystagmus, a condition that causes involuntary eye movements.
DJ said being selected for the treatment felt 'very fortuitous'.
She told PA the couple had a 'chance encounter' with Professor Michel Michaelides, a consultant retinal specialist at Moorfields Eye Hospital and professor of ophthalmology at the UCL Institute of Ophthalmology, at a conference about two months before their son was formally diagnosed with LCA4.
'We knew he had LCA, we didn't know his gene variant,' she added.
'Michel was speaking at this LCA family conference in Philadelphia, and we got his contact information on the off chance that Jace would have had a version of LCA that he and his team were researching.
'Hearing the genetic diagnosis of LCA and knowing this is the exact version that Dr Michaelides and Bainbridge and their whole team at Moorfields were researching, there was almost an excitement in the room when his results were being read.
'We started the conversations almost immediately after getting his report, and we're in constant contact with the Moorfields team ever since.'
The family travelled to London in September 2020, during the Covid-19 pandemic, and quarantined for two weeks in hospital housing.
'Jace's surgery was the last day in September of 2020,' DJ said. 'He went in happy as a clam, the staff was amazing in keeping him well rested and entertained, and Brendan and myself too.
'The surgery was pretty quick. He was only under for about an hour. He has four little, kind of, I won't even call them scars, just really like pinpoints, in his eye from where they actually injected the gene therapy.
'And he came out of surgery dancing, singing, making all the nursing staff laugh. He was happy to be eating afterwards and back in our arms.
'His recovery, other than having to tolerate an eye patch for a couple of days and some drops that he didn't really like, it was pretty easy.'
Brendan said he noticed a difference within the first month when his son reacted to the sun shining through a window.
'He kind of pulled himself back,' he said. 'It wasn't just even an eye shut, it was more of a physical reaction.
'And I remember welling up and getting really emotional because that was the first time that Jace ever had any reaction to any sort of light stimulus or anything of the sort.
'From there, it's been pretty amazing.'
It is not yet known if the gene therapy will have a permanent impact on Jace's vision.
DJ said: 'We've been prepped that at some point nature kind of takes over the way that nature intended.
'I think we don't expect this to be the treatment that gets him through the rest of his life, there's always going to be changes likely in his vision, but at a certain point, too technology is getting better every single day.
'Just being able to have more children treated through this genetic therapy is going to help to give more context to what's happening within the LCA4 community.
'And our hope is that this treatment becomes more mainstreamed, and maybe if he does start to lose his vision down the road if he has a retina that's still intact, maybe there is the option for retreatment down the road.
'But this first step was huge in being able to make that a reality.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
NOVEL IMMUNOLOGIC SURVEILLANCE STUDY PROVIDES NEW INSIGHTS INTO POST-PANDEMIC RETURN OF RESPIRATORY VIRUSES
Ongoing clinical research study in US children documents the rebound of endemic respiratory viruses, builds foundation for expediting future vaccines and treatments AURORA, Colo., Aug. 7, 2025 /PRNewswire/ -- The first paper from a multi-year clinical research study has been published in The Lancet Infectious Diseases: Dynamics of Endemic Virus Re-emergence in Children in the USA Following the COVID-19 Pandemic (2022-2023): A Longitudinal Immunoepidemiologic Surveillance Study and demonstrates how the approach can improve modeling to better predict future outbreaks. The paper shares findings from a multicenter clinical research study, one of many studies that are part of the recently launched PREMISE (Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology) program, led by Dr. Daniel Douek at the National Institutes of Health's (NIH) Vaccine Research Center (VRC). Data collected during the first year of the PREMISE study, 2022-2023, shows for the first time how non-pharmaceutical interventions such as masking and distancing targeted towards SARS-CoV-2 during the pandemic also decreased circulation rates of and population immunity to common respiratory pathogens in children. The study provides new evidence-based insight into what was driving the large post-pandemic rebound in these diseases and enables more accurate predictions for the future. This study is a partnership between PREMISE and clinical research sites at academic institutions led by principal investigator Kevin Messacar, MD, PhD, infectious disease specialist at Children's Hospital Colorado, at the central site at University of Colorado Anschutz Medical Campus and Children's Hospital Colorado with additional study sites at University of North Carolina, Weill Cornell Medicine and the University of Alabama at Birmingham. The PREMISE study conducted immunologic surveillance on children younger than 10 years old, by enrolling them and following them for over a year. Through repeat blood sampling, the team could determine what children at varying young ages had immunity to and what they were susceptible to. Through respiratory sampling during illness, researchers were able to determine what infections they experienced. The data showed that most younger children lacked immunity to many normal respiratory viruses during the pandemic, suggesting they had not been exposed, as they typically would have, due to prevention measures in place. Following the lifting of pandemic measures, the level of immunity rose across all pathogens studied, reflective of the unprecedented widespread resurgence of these viruses in children after the end of the pandemic. While most research studies target a specific disease, samples from PREMISE were tested for many common and emerging respiratory viruses, including RSV, influenza and enterovirus D68 (EV-D68), which can cause the polio-like illness, acute flaccid myelitis. The data allowed experts to recreate past circulation patterns and model predictions for future outbreaks with greater accuracy and precision. They showed that PREMISE data from 2022-23 could be used to accurately predict the subsequent wave of disease of the emerging pathogen EV-D68 that occurred in 2024. "Four cohorts of almost 1,000 children have provided an invaluable bank of samples and data," said lead author Hai Nguyen-Tran, MD, infectious disease specialist at Children's Hospital Colorado and assistant professor at University of Colorado School of Medicine. "These are being used to develop 'on the shelf' medical countermeasures, such as antibody treatments and vaccines, for pathogens of interest. Instead of starting from scratch, this study gives us a head start to understand, predict and prepare for future pandemics." Samples and data from the PREMISE study will also be used to learn which parts of viruses the human immune system attacks to become immune, so teams can better design new antibody treatments and effective vaccines to mimic this response. "In the future, this type of immune surveillance can be used to better understand the impact of public interventions on population immunity and future waves of disease," said Dr. Messacar, who is also a professor at University of Colorado School of Medicine. "PREMISE is a great example of a successful research partnership between NIH scientists and clinical researchers in academia, leading to concrete deliverables such as vaccine candidates and monoclonal antibodies that can directly impact public health." This study is fully funded by a subcontract with Frederick National Laboratory for Cancer Research (FNLCR), currently operated by Leidos Biomedical Research, Inc. through Agreement 21X192QT1. FNLCR funding was provided by the NIH Vaccine Research Center within NIAID. The total project funding is $7.98 million over five years. No financing for this project was supplied by nongovernmental sources. ABOUT CHILDREN'S HOSPITAL COLORADOChildren's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Media Contact: Rachael Fowler, Children's Hospital Colorado 24/7 media line: 303-890-8314media@ View original content to download multimedia: SOURCE Children's Hospital Colorado
Yahoo
04-08-2025
- Yahoo
Plastics 'crisis' is costing $1.5tn in global deaths and injuries, report says
A global 'plastics crisis' is costing governments and taxpayers $1.5 trillion annually as they try to cope with the escalating injury, disability and death caused by the substance polluting our land, sea and bodies, according to a new report by a leading medical journal. Plastic production is on course to triple by 2060, less than 10% of it is recycled, and around 8,000 megatons now pollute the planet, according to a review of recent studies published Sunday by The Lancet. This causes harm at every stage of its lifecycle: from the extraction of fossil fuels and production, to its use by humans and eventual disposal into the environment, the British publication said. 'Plastics are a grave, growing, and under-recognised danger to human and planetary health,' it said. 'Plastics cause disease and death from infancy to old age' and are 'contributing to climate change, pollution, and biodiversity loss.' These harms 'fall disproportionately upon low-income and at-risk populations,' it added. This is the latest dire warning by experts about the ubiquity and threat posed by plastic, which journal called 'the defining material of our age.' After decades of scientists warning about plastic being found in the oceans and rivers, microplastics are now being discovered inside humans — including in breast milk and brain tissue. Sunday's release marked the start of a new monitoring system called 'The Lancet Countdown on health and plastics,' which it says will track political attempts to combat the problem. It was launched to coincide with the latest and final round of talks in Geneva, Switzerland, where 175 countries are trying to forge the world's first Global Plastics Treaty. Campaigners hope the talks, starting Tuesday through Aug. 14, will result in mandatory targets for reducing plastic production. A group of countries, including China, Russia, Iran and Saudi Arabia, have so far opposed these measures, instead lobbying for increased plastic recycling instead. According to The Lancet, such petrochemical giants are a 'key driver' of spiraling plastic production, as they pivot their businesses toward plastic in response to the global decline in demand for fossil energy. Different plastics are made from up to 16,000 chemicals, which 'enter the human body via ingestion, inhalation, and dermal absorption,' often from food and drink containers and packaging, the study said. Unborn babies, infants and young children are 'especially at risk,' with harms including miscarriage, physical malformations, reduced cognitive function and diabetes, it said. For adults, the risks include cardiovascular disease, stroke and cancer. 'Given the considerable gaps in knowledge of plastic chemicals, it is reasonable to conclude that the full extent of these chemicals' harms to health is underestimated and that the burden of disease currently attributed to them is undercounted,' it added. The Lancet quoted one study estimating the global costs of these diseases as $1.5 trillion. 'It is now clear that the world cannot recycle its way out of the plastic pollution crisis,' The Lancet said. 'Control of the plastics crisis will require continuing research coupled with the science-driven interventions — laws, policies, monitoring, enforcement, incentives, and innovations.' This article was originally published on


NBC News
04-08-2025
- NBC News
Plastics 'crisis' is costing $1.5tn in global deaths and injuries, report says
A global 'plastics crisis' is costing governments and taxpayers $1.5 trillion annually as they try to cope with the escalating injury, disability and death caused by the substance polluting our land, sea and bodies, according to a new report by a leading medical journal. Plastic production is on course to triple by 2060, less than 10% of it is recycled, and around 8,000 megatons now pollute the planet, according to a review of recent studies published Sunday by The Lancet. This causes harm at every stage of its lifecycle: from the extraction of fossil fuels and production, to its use by humans and eventual disposal into the environment, the British publication said. 'Plastics are a grave, growing, and under-recognised danger to human and planetary health,' it said. 'Plastics cause disease and death from infancy to old age' and are 'contributing to climate change, pollution, and biodiversity loss.' These harms 'fall disproportionately upon low-income and at-risk populations,' it added. This is the latest dire warning by experts about the ubiquity and threat posed by plastic, which journal called 'the defining material of our age.' After decades of scientists warning about plastic being found in the oceans and rivers, microplastics are now being discovered inside humans — including in breast milk and brain tissue. Sunday's release marked the start of a new monitoring system called 'The Lancet Countdown on health and plastics,' which it says will track political attempts to combat the problem. It was launched to coincide with the latest and final round of talks in Geneva, Switzerland, where 175 countries are trying to forge the world's first Global Plastics Treaty. Campaigners hope the talks, starting Tuesday through Aug. 14, will result in mandatory targets for reducing plastic production. A group of countries, including China, Russia, Iran and Saudi Arabia, have so far opposed these measures, instead lobbying for increased plastic recycling instead. According to The Lancet, such petrochemical giants are a 'key driver' of spiraling plastic production, as they pivot their businesses toward plastic in response to the global decline in demand for fossil energy. Different plastics are made from up to 16,000 chemicals, which 'enter the human body via ingestion, inhalation, and dermal absorption,' often from food and drink containers and packaging, the study said. Unborn babies, infants and young children are 'especially at risk,' with harms including miscarriage, physical malformations, reduced cognitive function and diabetes, it said. For adults, the risks include cardiovascular disease, stroke and cancer. 'Given the considerable gaps in knowledge of plastic chemicals, it is reasonable to conclude that the full extent of these chemicals' harms to health is underestimated and that the burden of disease currently attributed to them is undercounted,' it added. The Lancet quoted one study estimating the global costs of these diseases as $1.5 trillion. 'It is now clear that the world cannot recycle its way out of the plastic pollution crisis,' The Lancet said. 'Control of the plastics crisis will require continuing research coupled with the science-driven interventions — laws, policies, monitoring, enforcement, incentives, and innovations.'